Kirkland & Ellis is advising Bain Capital Private Equity and Cinven who have entered into definitive agreements to acquire Lonza Specialty Ingredients (“LSI”), a division of Lonza AG, for a total enterprise value of CHF 4.2 billion. LSI is a world-leading provider of specialty chemicals for microbial control solutions, used to eliminate or control harmful and unwanted micro-organisms. LSI’s products are critical ingredients in disinfectants, preservatives, sanitisers, personal care products, as well as coatings and other industrial uses. The business also produces a range of other specialty chemicals, centred around its unique production facility in Switzerland. Headquartered in Basel, Switzerland, LSI has approximately 2,800 employees, 11 R&D centres and 17 manufacturing sites across the world. The business serves circa 5,300 customers across a wide range of end-markets. Read the Bain Capital press release

The Kirkland team was led by transactional partners Adrian Maguire, Rory Mullarkey, Jacob Traff and Dan Clarke and associates Claire Rushton, Max Mugnaioni, Jelani Okoruwa and Molly Beck; tax partners Tim Lowe and Mike Carew; antitrust & competition partner Paula Riedel and technology & IP transactions associate John Patten.